Tessera Therapeutics
A scientist role at Tessera Therapeutics supporting the development of oligonucleotide technologies within the company’s Gene Writing platform. The position is part of the Oligo Foundry and contributes to advancing scalable therapeutic approaches through collaboration with cross-functional teams and scientific stakeholders.
Headquarters
Somerville, Massachusetts, United States
Company Size
201-500 employees
Tessera Therapeutics is an early‑stage life sciences company and a Flagship Pioneering venture developing Gene Writing™, a platform technology that programs engineered proteins to write RNA templates into the genome. The approach is designed to install, replace, or remove DNA sequences—enabling potentially durable, one‑time genetic medicines for inherited and other diseases. Tessera combines proprietary molecular engineering and delivery efforts to build a pipeline of therapeutic programs and partnerships aimed at translating the Gene Writing platform into clinical treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Tessera Therapeutics.
Research Associate
Agilent Technologies
Mixed Modality (Oligonucleotide) Advisor
Eli Lilly and Company
Scientist/Sr Scientist - Oligonucleotide Chemistry
Eli Lilly and Company
Associate Scientist II of MSAT
Strand Therapeutics
Oligonucleotide Senior Scientist
Eurofins
Principal Research Associate - Oligonucleotide Chemistry
Alloy Therapeutics